Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRC #mmsm #myelom #USMIRC @USMIRCNEWS @CurrentOncology mdpi.com/1718-7729/33/6/355

🧵 Post-BCMA Failure in RRMM: What should we do next? 🤔 A new multicenter USMIRC/US academic center real-world analysis provides practical insights into sequencing after BCMA-directed therapy failure. Here are the key takeaways for clinicians 👇 1️⃣ BCMA-directed therapy failure is becoming increasingly common, yet the optimal sequencing strategy remains undefined. 📌 This analysis integrates 3 multicenter real-world cohorts evaluating: 🔹 BCMA CAR-T 🔹 BCMA bispecific antibodies 🔹 Talquetamab (GPRC5D) #mmsm #myeloma #MedEd #Medtwitter #USMIRC @oncodaily @USMIRCNEWS @US_HMC @CurrentOncology @MedwatchKate @Larvol #المايلوما #سرطان_الدم

mdpi.com/1718-7729/33/6/355 #MedEd #medtwitter #WorldCup #USMIRC #mmsm #myeloma

🚨 MonumenTAL-3 (NEJM 2026): Talquetamab Beats the Old Standard of Care… But the Biggest Question Wasn’t Answered! 🧵 Can Talquetamab Truly Move Earlier—and Where Does It Fit After BCMA-Directed Therapy? Let’s Discuss the Ups, Downs & Future. 1/ Talquetamab continues to reshape the RRMM landscape. The Phase III #MonumenTAL3 trial compared: ✅ Talquetamab Daratumumab Pomalidomide (Tal-DP) ✅ Talquetamab Daratumumab (Tal-D) vs ✅ DPd Patients had ≥1 prior line of therapy. #mmsm #myeloma #MedEd #Mestwitter #USMIRC @US_HMC @USMIRCNEWS @MedwatchKate @Larvol @oncodaily

A huge congratulations to one of my closest friends and an exceptional colleague @kczmj on your well-deserved promotion to Director of Pharmacy – Advanced Therapeutics at @KUcancercenter ! 🎉 Your dedication, leadership, and passion for advancing patient care have always inspired those around you. I couldn’t be happier to see your hard work recognized. Wishing you continued success in this exciting new role—you’ve truly earned it! Congratulations, my friend! 👏🎊 #Leadership #AdvancedTherapeutics #Pharmacy #KUMC @oncodaily @MedwatchKate

Allogeneic hematopoietic cell transplantation following chimeric antigen receptor T-cell (CAR-T) therapy in B-cell acute lymphoblastic leukemia (B-ALL): A systematic review and meta-analysis. | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1200… @KUcancercenter @USMIRCNEWS

Outcomes after unrelated donor allogeneic hematopoietic cell transplantation in age ≥65 using post-transplant cyclophosphamide | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1200… @KUcancercenter @mrf_org @USMIRCNEWS

🔹 Is There Still a Place for Mezigdomide in the Modern Myeloma Treatment Landscape? Let’s see what data we have before we jump to conclusions? 🧵 ASCO 2026 | SUCCESSOR-2: Mezigdomide Kd : 1/🔬 let’s start with the study Design (very Critical) SUCCESSOR-2 randomized RRMM patients with: ✅ Prior lenalidomide exposure ✅ Prior anti-CD38 monoclonal antibody exposure ✅ ≥1 prior line of therapy To receive: 🟢 Mezigdomide Carfilzomib Dexamethasone (MeziKd) vs ⚪ Carfilzomib Dexamethasone (Kd) Primary endpoint: PFS #ASCO2026 #MultipleMyeloma #mmsm #USMIRC #MedEd #medtwitter @US_HMC @USMIRCNEWS @MedwatchKate @Larvol @oncodaily

From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma. Expert Review of Hematology. 2026 @USMIRCNEWS @KUcancercenter doi.org/10.1080/17474086.202…

Always proud of our superstar pharmacist leader @kczmj ! Her outstanding work, innovation, and dedication are helping shape the future of cellular therapy. #mmsm #myeloma #MedEd #medtwitter #USMIRC @Larvol @ASTCT @US_HMC @USMIRCNEWS @MedwatchKate @oncodaily astct.org/Nucleus/Article/me…

A simple comparison of Teclistamab studies in relapsed multiple myeloma—single agent vs combination therapy, and early vs late relapse settings. #mmsm #myeloma #MedEd #medtwitter #USMIRC @USMIRCNEWS @Larvol @MedwatchKate @oncodaily @US_HMC

The new interactive online edition of ONCOLOGY® is here. Explore the May 2026 issue through a dynamic digital experience featuring expert insights, oncology updates, and more - all designed for easier engagement and discovery. Check it out: hubs.li/Q04jnLr10 Special thanks to @DrJulieVose @Neil_Iyengar @Abdallah81MD for helping bring this to life!

⏳🔥 COUNTDOWN SEASON IS ON 🔥⏳ ⚽ World Cup 2026 — ONLY 14 DAYS LEFT 🌎
🧬 National ICE-T Congress — Orlando, FL — 51 DAYS LEFT 🚀
🏙️ ICE-T Regional Symposium — Kansas City, KS — 163 DAYS LEFT 🔬 Exciting months ahead! 👀 #WorldCup2026 #ICETCongress #CARt #CellTherapy #MMsm #Hematology #Oncology #Immunotherapy #mmsm #myeloma #MedEd #medtwitter #USMIRC @USMIRCNEWS @US_HMC @MedwatchKate @oncodaily @Larvol

From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myeloma By @mumairmushtaq @AtrashShebli @Abdallah81MD @USMIRCNEWS #mmsm #myeloma @oncodaily tandfonline.com/doi/full/10.…

Soon #USMIRC #MedEd -#medtwitter #mmsm #Myeloma

Long-Term Gynecologic and Reproductive Health in Female Survivors of Allo-HCT... sciencedirect.com/science/ar… @KUcancercenter @mrf_org @USMIRCNEWS

Impact of CD34 Graft Cell Dose on Outcomes After Haploidentical BMT ... sciencedirect.com/science/ar… @KUcancercenter @mrf_org @USMIRCNEWS

High-Risk Cytogenetic Multiple Myeloma Remains a Therapeutic Challenge: A 15-Year Real-World Analysis #mmsm #myeloma #MedEd #medtwitter @USMIRCNEWS #USMIRC mdpi.com/1718-7729/33/5/249

A Blood Paper.. 🩸 Grateful to see our work published in Blood. A journey shaped by patients, mentors, collaborators, and years of shared effort and hope. @KUcancercenter @KUMedCenter @mrf_org @USMIRCNEWS

🚨 At the 2026 National ICE-T Conference in Charlotte, @myelomadoctor discussed the potential role of the investigational FcRH5xCD3 bispecific cevostamab in helping fill critical gaps in the multiple myeloma treatment landscape @CancerNetwrk 🩸 #MultipleMyeloma #Bispecifics #ICETCongress @oncodaily @USMIRCNEWS @US_HMC @MedwatchKate @Larvol #mmsm #myeloma cancernetwork.com/view/cevos…